By Chantelle Muzanenhamo
Harare – Zimbabwe has been selected as one of ten countries globally to roll out lenacapavir, a breakthrough development in the fight against HIV, the U.S. Embassy in Zimbabwe announced on its official X account.
“Yes Zimbabwe, it’s happening! We are excited to announce that Zimbabwe was selected as one of the ten countries globally to roll out lenacapavir, a breakthrough development in the fight against HIV,” the embassy posted.
Lenacapavir, developed through a partnership with @GileadSciences and @GlobalFund, is the first twice-yearly HIV prevention medicine. In a large-scale clinical trial, more than 99% of people on lenacapavir remained HIV negative, offering hope for millions worldwide.
The announcement emphasized that the rollout goes beyond medication, stating:
“But this is more than medicine it advances us on a pathway to a safer, stronger, and healthier future!”
Special focus will be given to pregnant and breastfeeding women, with the aim of protecting the next generation. The initiative also strengthens healthcare systems and ensures that “by making lenacapavir more affordable and accessible, no one is left behind.”
The embassy concluded with a message of optimism:
“This is American leadership at its best: driving innovation, and building a world where children, mothers, and communities can thrive. Together, we’re not just fighting HIV we’re winning.”
The rollout marks a major milestone in Zimbabwe’s efforts to end new HIV infections and demonstrates the potential of international collaboration to address public health challenges.